TGTX TG THERAPEUTICS, INC.

Overview and Growth

TG THERAPEUTICS, INC. generated $616.29M of revenue in fiscal 2025, with net income of $447.18M and an operating cash outflow of $24.77M. Revenue of $616.29M sets the scale for evaluating how effectively sales translated into profit and cash during the year. The top line expanded 87.3% from $329.00M in fiscal 2024, increasing the company’s operating scale. On a per-share basis, diluted EPS was $2.77, which connects the reported earnings outcome with the company’s diluted share count. Revenue equaled 0.58x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

After reported cost of revenue, the company retained $515.57M as gross profit before recognizing operating expenses and other items. The gross-profit relationship equaled 83.7% of revenue, quantifying the portion retained before operating expenses were recognized. Operating income was $123.32M, the earnings remaining from reported operations after the company’s recognized operating cost structure. Relative to revenue, operating income represented 20.0%, showing how efficiently sales converted into operating profit. After all reported below-operating-line items, the company recorded net income of $447.18M for the fiscal year. The final earnings result represented 72.6% of revenue, connecting the absolute net income figure with the company’s top-line scale. The earnings statement records $107.39M of pretax income, the profit base against which the reported tax provision can be assessed. Measured against revenue, pretax income equaled 17.4%, adding a pre-tax profitability layer between revenue and net income. An income-tax benefit of $339.79M improved the final result relative to pretax income or loss. The effective tax-benefit relationship was 316.4% of positive pretax income. The relationship between net income and period-end equity was 69.0%, indicating the profitability achieved on book capital. Return on period-end assets was 42.1%, connecting net income with the company’s total asset base.

Liquidity and Capital Structure

The company held $1.06B of assets against $415.23M of liabilities and $648.02M of equity, revealing how the asset base was financed. The near-term balance sheet paired $630.76M of current assets with $153.76M of current liabilities at the reporting date. The current ratio was 4.1x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Reported cash and equivalents were $79.15M, separating immediately recognizable cash resources from the rest of the current-asset base. Cash and equivalents represented 51.5% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Total debt was $245.65M, establishing the amount of borrowing carried within the company’s capital structure. Against book equity, debt measured 0.38x, placing the company’s financial leverage in clear balance-sheet terms. Debt represented 23.1% of total assets, placing borrowing in the context of the company’s full resource base. The liabilities-to-assets relationship was 39.1%, placing reported obligations against the full positive asset balance. The cash-to-assets relationship was 7.4%, comparing reported cash and equivalents with the full positive asset balance. The asset base changed 84.1% from $577.69M in fiscal 2024, leaving current total assets higher year over year. Book equity was 191.4% higher than fiscal 2024 equity of $222.36M, showing how shareholder capital changed year over year.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $24.77M, rather than cash generation from operations. Capital expenditures used $214.00K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. Negative free cash flow was $24.99M, leaving a cash deficit after capital spending and reducing financial flexibility. Relative to revenue, the post-investment cash deficit represented 4.1%. The cash deficit after capital spending represented 2.3% of the period-end asset base.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.